Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients (Q44664395)

5 December 2017

Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients (English)

1 reference

5 December 2017

1 reference

Gin H

1

1 reference

5 December 2017

Roudaut MF

2

1 reference

5 December 2017

Vergnot V

3

1 reference

5 December 2017

Baillet L

4

1 reference

5 December 2017

Rigalleau V

5

1 reference

5 December 2017

1 November 2003

1 reference

5 December 2017

Diabetes and Metabolism

1 reference

5 December 2017

29

1 reference

5 December 2017

5

1 reference

5 December 2017

505-508

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Insulin resistance and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Glucose control and cardiovascular complications: the VA Diabetes Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Insulin sensitivity, insulin action, and fibrinolysis activity in nondiabetic and diabetic obese subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Association of Blood Pressure With Fibrinolytic Potential in the Framingham Offspring Population

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor Type I by proinsulin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Combination therapies with insulin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970064-2

7 January 2021

10.1016/S1262-3636(07)70064-2

Identifiers

DOI

1 reference

5 December 2017

1 reference